494 related articles for article (PubMed ID: 36496996)
1. Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
Kwon DK; Kwatra M; Wang J; Ko HS
Cells; 2022 Nov; 11(23):. PubMed ID: 36496996
[TBL] [Abstract][Full Text] [Related]
2. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
Zesiewicz TA; Sullivan KL; Hauser RA
Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
[TBL] [Abstract][Full Text] [Related]
3. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
[TBL] [Abstract][Full Text] [Related]
4. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
Dias CMV; Leal DAB; Brys I
Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453
[No Abstract] [Full Text] [Related]
5. Noradrenergic drugs for levodopa-induced dyskinesia.
Colosimo C; Craus A
Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Thanvi B; Lo N; Robinson T
Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
[TBL] [Abstract][Full Text] [Related]
7. Amantadine Extended-Release (GOCOVRI
Paik J; Keam SJ
CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
9. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Duty S
CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
[TBL] [Abstract][Full Text] [Related]
10. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
Schaeffer E; Pilotto A; Berg D
CNS Drugs; 2014 Dec; 28(12):1155-84. PubMed ID: 25342080
[TBL] [Abstract][Full Text] [Related]
12. New insights into pathogenesis of l-DOPA-induced dyskinesia.
Zheng C; Zhang F
Neurotoxicology; 2021 Sep; 86():104-113. PubMed ID: 34331976
[TBL] [Abstract][Full Text] [Related]
13. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
14. [Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Thomsen BL; Herz DM; Siebner HR; Løkkegaard A
Ugeskr Laeger; 2017 Mar; 179(10):. PubMed ID: 28263159
[TBL] [Abstract][Full Text] [Related]
15. Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
Wang CC; Wu TL; Lin FJ; Tai CH; Lin CH; Wu RM
Eur J Neurol; 2022 Apr; 29(4):1044-1055. PubMed ID: 34962701
[TBL] [Abstract][Full Text] [Related]
16. Non-dopaminergic treatments for motor control in Parkinson's disease.
Fox SH
Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of striatal Ca
Caulfield ME; Vander Werp MJ; Stancati JA; Collier TJ; Sortwell CE; Sandoval IM; Manfredsson FP; Steece-Collier K
Neurobiol Dis; 2023 Jun; 181():106111. PubMed ID: 37001610
[TBL] [Abstract][Full Text] [Related]
18. Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Cesaroni V; Blandini F; Cerri S
Expert Opin Ther Targets; 2022 Oct; 26(10):837-851. PubMed ID: 36469635
[TBL] [Abstract][Full Text] [Related]
19. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
[TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
